Kincell Bio Overview

  • Year Founded
  • 2023

Year Founded

  • Status
  • Acquired/​Merged

  • Employees
  • 82

Employees

  • Latest Deal Type
  • M&A

Kincell Bio General Information

Description

Operator of a contract development and manufacturing organization intended to advance autologous and allogeneic cell therapies for patients. The company streamlines CMC development, applying expertise in analytical and processing development and GMP manufacturing to test and release from early clinical to pivotal studies and product launch, enabling researchers and laboratories to process development and manufacturing from early clinical to pivotal supply and commercial launch, ensuring rapid timelines without compromising on quality.

Contact Information

Ownership Status
Acquired/Merged
Financing Status
Formerly VC-backed
Corporate Office
  • 1622 North West 55th Place
  • Gainesville, FL 32653
  • United States
Primary Industry
Biotechnology
Other Industries
Drug Discovery
Vertical(s)
Corporate Office
  • 1622 North West 55th Place
  • Gainesville, FL 32653
  • United States

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Kincell Bio Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
4. Merger/Acquisition 17-Sep-2026 Completed Generating Revenue
3. Early Stage VC 15-May-2025 Completed Generating Revenue
2. Early Stage VC (Series A) 26-Jul-2023 $36M $36M Completed Generating Revenue
1. Spin-Off 01-Jan-2023 Completed Startup
To view Kincell Bio’s complete valuation and funding history, request access »

Kincell Bio Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Kincell Bio Former Investors (3)

Investor Name Investor Type Holding Investor Since Participating Rounds
Inceptor Bio VC-Backed Company
Kineticos Life Sciences Management Venture Capital Minority
NewSpring Capital Growth/Expansion Minority
To view Kincell Bio’s complete investors history, request access »

Kincell Bio Investments (1)

Kincell Bio’s most recent deal was a Corporate Asset Purchase with Imugene (Cell Therapy Manufacturing Facility in North Carolina) for . The deal was made on 16-Apr-2024.

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
Imugene (Cell Therapy Manufacturing Facility in North Carolina) 16-Apr-2024 Corporate Asset Purchase Buildings and Property
To view Kincell Bio’s complete investments history, request access »

Kincell Bio FAQs

  • When was Kincell Bio founded?

    Kincell Bio was founded in 2023.

  • Where is Kincell Bio headquartered?

    Kincell Bio is headquartered in Gainesville, FL.

  • What is the size of Kincell Bio?

    Kincell Bio has 82 total employees.

  • What industry is Kincell Bio in?

    Kincell Bio’s primary industry is Biotechnology.

  • Is Kincell Bio a private or public company?

    Kincell Bio is a Private company.

  • What is Kincell Bio’s current revenue?

    The current revenue for Kincell Bio is .

  • How much funding has Kincell Bio raised over time?

    Kincell Bio has raised $58M.

  • Who are Kincell Bio’s investors?

    Inceptor Bio, Kineticos Life Sciences Management, and NewSpring Capital have invested in Kincell Bio.

  • When was Kincell Bio acquired?

    Kincell Bio was acquired on 17-Sep-2026.

  • Who acquired Kincell Bio?

    Kincell Bio was acquired by Kincellis Advanced Therapies.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process